BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12365891)

  • 21. RADPLAT: an alternative to surgery?
    Alkureishi LW; de Bree R; Ross GL
    Oncologist; 2006 May; 11(5):469-80. PubMed ID: 16720847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interval pathologic assessments in patients treated with concurrent hyperfractionated radiation and intraarterial cisplatin (HYPERRADPLAT).
    Valentino J; Spring PM; Shane M; Arnold SM; Regine WF
    Head Neck; 2002 Jun; 24(6):539-44. PubMed ID: 12112550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose intra-arterial cisplatin therapy followed by radiation therapy for advanced squamous cell carcinoma of the head and neck.
    Wilson WR; Siegel RS; Harisiadis LA; Davis DO; Nguyen HH; Bank WO
    Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):809-12. PubMed ID: 11448355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer.
    Mitsudo K; Shigetomi T; Fujimoto Y; Nishiguchi H; Yamamoto N; Furue H; Ueda M; Itoh Y; Fuwa N; Tohnai I
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1428-35. PubMed ID: 20605340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
    Hoebers FJ; Pluim D; Verheij M; Balm AJ; Bartelink H; Schellens JH; Begg AC
    Int J Cancer; 2006 Aug; 119(4):750-6. PubMed ID: 16550603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
    Kovács AF; Mose S; Böttcher HD; Bitter K
    Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensification regimen 2 for advanced head and neck squamous cell carcinomas.
    Grecula JC; Schuller DE; Rhoades CA; Au JL; Nag S; Bauer CJ; Agrawal A; Martinez-Monge R; Johnson A; Young D; Gahbauer RA
    Arch Otolaryngol Head Neck Surg; 1999 Dec; 125(12):1313-8. PubMed ID: 10604408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
    Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS
    J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
    Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis.
    Rades D; Kronemann S; Meyners T; Schild SE; Hakim SG
    Oral Oncol; 2010 Jul; 46(7):549-52. PubMed ID: 20435508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term results.
    Bertino G; Occhini A; Falco CE; Porta C; Corbella F; Colombo S; Balcet V; Morbini P; Zappoli F; Azzaretti A; Rodolico G; Tinelli C; Benazzo M
    BMC Cancer; 2009 Sep; 9():313. PubMed ID: 19732449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
    Rischin D; Peters LJ; O'Sullivan B; Giralt J; Fisher R; Yuen K; Trotti A; Bernier J; Bourhis J; Ringash J; Henke M; Kenny L
    J Clin Oncol; 2010 Jun; 28(18):2989-95. PubMed ID: 20479425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
    Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
    Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
    Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
    J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
    Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
    Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
    Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
    Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.
    Planting AS; de Mulder PH; de Graeff A; Verweij J
    Eur J Cancer; 1997 Jan; 33(1):61-5. PubMed ID: 9071901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
    van den Broek GB; Rasch CR; Pameijer FA; Peter E; van den Brekel MW; Tan IB; Schornagel JH; de Bois JA; Zijp LJ; Balm AJ
    Cancer; 2004 Oct; 101(8):1809-17. PubMed ID: 15386309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.